Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Ring, A Sestak, I Baum, M Howell, Anthony Buzdar, A Dowsett, M Forbes, J F Cuzick, J
Ring, A
Sestak, I
Baum, M
Howell, Anthony
Buzdar, A
Dowsett, M
Forbes, J F
Cuzick, J
Citations
Altmetric:
Abstract
The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination. We have conducted a retrospective analysis to examine the effects of comorbidities and age on treatment received, breast cancer-related mortality, and competing causes of mortality.
Description
Date
2011-11-10
Publisher
Collections
Keywords
Type
Article
Citation
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. 2011, 29 (32):4266-72 J Clin Oncol